Please assess the completion status of the following clinical trial:

Trial Title: Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion criteria:~1. Signed and dated ICF (Informed Consent Form)~2. Male or female on diet and exercise regime and on stable background metformin \> or equal to 1500 mg or maximun dose according to local label~3. HBA1c (Glicoslated Hemoglobin) \> or equal to 8% and \< or equal to 10.5 % at Visit 1~4. HbA1c \> or equal to 7 and \< or equal to 10.5 at Visit 4~5. Age \> or equal to 18 years~6. BMI (Body Mass Index) \< or equal to 45~Exclusion criteria:~1. Uncontrolled hyperglycemia during open label period and placebo add on run-in period~2. Use of any other antidiabetic~3. Renal function below 60 ml/min/1.73 m2~4. Antiobesity drugs or aggresive diets~5. Gastorintestinal surgeries~6. Current systemic steroids or uncontrolled endocrine disorders other than Diabetes Type 2~7. Acute coronary syndrome and stroke within 3 months of informed consent~8. Known allergies to DPP-IV (Dypeptidil Peptidase IV) or SGLT-2 (Sodium Glucose Transporter 2) inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin 10 mg dose (Type: EXPERIMENTAL): Empagliflozin open label treatment period
- Placebo add on 10 mg dose (Type: EXPERIMENTAL): Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in
- Empagliflozin/Linagliptin 25/5 mg Dose (Type: EXPERIMENTAL): Empagliflozin / Linagliptin 25/5 mg Dose FDC active
- Empagliflozin/Linagliptin 10/5 mg Dose. (Type: EXPERIMENTAL): Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
- Empagliflozin/Linagliptin 10/5 mg Dose (Type: EXPERIMENTAL): Empagliflozin / Linagliptin 10/5 mg Dose FDC active
- Empagliflozin 25 mg dose (Type: EXPERIMENTAL): Empagliflozin open label treatment period
- Empagliflozin/Linagliptin 25/5 mg Dose. (Type: EXPERIMENTAL): Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
- Placebo add on 25 mg dose (Type: EXPERIMENTAL): Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in

Based on this trial design, predict the completion outcome and termination type (if applicable).